March 2019, Vol 12, Tenth Annual Payers' Guide
American Health & Drug Benefits is pleased to bring you the Tenth Annual Payers’ Guide to New FDA Approvals. As has now become a tradition of this publication, the goal of this Guide is to offer payers, providers, Pharmacy & Therapeutics committees, and other healthcare stakeholders an overview of the novel pharmaceuticals approved by the US Food and Drug Administration (FDA) in 2018.
Before we discuss the new indications for oncology therapies approved in 2018, a word about the novel drugs entering the market is in order, considering the new record set last year in drug approvals in the United States.
Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults
raine is a neurologic disease that affects approximately 37 million people in the United States and comprises several subtypes, including common migraine, complicated migraine, retinal migraine, chronic migraine, and cluster headaches.
Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
Prostate cancer, the second most common type of cancer in men, is expected to affect 11.6% of all men during their lifetime. In fact, more than 3 million men in the United States are living with prostate cancer.
Ilumya (Tildrakizumab-asmn), Interleukin-23 Antagonist, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis
Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination FDA Approved for the Treatment of Waldenström’s Macroglobulinemia
In 1944, Jan G. Waldenström, MD, published his observations about a series of patients who presented with anemia, hepatosplenomegaly, hyperviscosity, bleeding, lymphoplasmacytic infiltrate in the bone marrow, and a large serum protein or “macroglobulin.”
Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Advanced Cutaneous Squamous-Cell Carcinoma
Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin Approved for Relapsed or Refractory Hairy-Cell Leukemia
Page 1 of 2
Results 1 - 10 of 17
Results 1 - 10 of 17